Evercore ISI Group:维持BridgeBio Pharma评级

证券之星
24 Dec 2024

evercore ISI Group:维持bridgebio pharma(BBIO.US)评级,由优于大市调整至优于大市评级,目标价由45.00美元调整至50.00美元。BridgeBio Pharma(BBIO.US)公司简介:BridgeBio Pharma是一家生物技术公司,专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。该公司有四个项目处于研发后期管线,专注于孟德尔遗传病、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10